

Statement of Deficiencies	(X1) Provider/Supplier/CLIA Identification Number 45D0899231	(X3) Date Survey Completed 11/04/2022
Name of Provider or Supplier Beaumont Internal Medicine & Geriatric Associates	Street Address, City, State 755 N 11th St Suite P5200, Beaumont, TX	
For information on the provider's plan to correct this deficiency, please contact the provider or the state survey agency.		

(X4) ID Prefix Tag	Summary Statement of Deficiencies
D0000	Based on a proficiency testing desk review survey performed on November 4, 2022, the laboratory was found to be out of compliance based on the following CONDITION LEVEL DEFICIENCIES: D2086 - 42 C.F.R. 493.803 Condition: Successful participation D6000 - 42 C.F.R. 493.1403 Condition: Laboratory Director, moderate complexity
D2016	<p>SUCCESSFUL PARTICIPATION CFR(s): 493.803(a)(b)(c)</p> <p>(a) Each laboratory performing nonwaived testing must successfully participate in a proficiency testing program approved by CMS, if applicable, as described in subpart I of this part for each specialty, subspecialty, and analyte or test in which the laboratory is certified under CLIA. (b) Except as specified in paragraph (c) of this section, if a laboratory fails to participate successfully in proficiency testing for a given specialty, subspecialty, analyte or test, as defined in this section, or fails to take remedial action when an individual fails gynecologic cytology, CMS imposes sanctions, as specified in subpart R of this part. (c) If a laboratory fails to perform successfully in a CMS-approved proficiency testing program, for the initial unsuccessful performance, CMS may direct the laboratory to undertake training of its personnel or to obtain technical assistance, or both, rather than imposing alternative or principle sanctions except when one or more of the following conditions exists: (1) There is immediate jeopardy to patient health and safety. (2) The laboratory fails to provide CMS or a CMS agent with satisfactory evidence that it has taken steps to correct the problem identified by the unsuccessful proficiency testing performance. (3) The laboratory has a poor compliance history.</p> <p>This CONDITION is not met as evidenced by: Based on a desk review of the Certification and Survey Provider Enhanced Reporting (CASPER) Report 155 Individual Laboratory Profile American Proficiency Institute (API) records, the laboratory failed to achieve satisfactory performance in two</p>

	<p>consecutive testing events in 2022 for Triiodothyronine, resulting in unsuccessful performance (refer to D2107), and failed to achieve an overall satisfactory performance for the subspecialty Endocrinology for two consecutive testing events in 2022 (refer to D2108).</p>
<p>D2107</p>	<p>ENDOCRINOLOGY CFR(s): 493.843(f)</p> <p>Failure to achieve satisfactory performance for the same analyte or test in two consecutive testing events or two out of three consecutive testing events is unsuccessful performance.</p> <p>This STANDARD is not met as evidenced by: Based on a desk review of the Certification and Survey Provider Enhanced Reporting (CASPER) Report 155 Individual Laboratory Profile and American Proficiency Institute (API) testing records from 2022, the laboratory failed to achieve a testing event score of satisfactory performance (80% or greater) for two consecutive testing events for the analyte Triiodothyronine in the subspecialty in Endocrinology. Two out of two overall testing event scores of unsatisfactory performance results in unsuccessful proficiency testing performance. The findings include: 1. A review of the CASPER Report 155 listed the following scores in 2022: 2022 Event 2: Triiodothyronine - 0% 2022 Event 3: Triiodothyronine - 40% 2. A proficiency desk review of API proficiency testing records from 2022 confirmed that the laboratory received the following scores the Triiodothyronine in the subspecialty Endocrinology: 2022 Event 2: Triiodothyronine - 0% 2022 Event 3: Triiodothyronine - 40%</p>
<p>D2108</p>	<p>ENDOCRINOLOGY CFR(s): 493.843(g)</p> <p>Failure to achieve an overall testing event score of satisfactory performance for two consecutive testing events or two out of three consecutive testing events is unsuccessful performance.</p> <p>This STANDARD is not met as evidenced by: Based on a desk review of the Certification and Survey Provider Enhanced Reporting (CASPER) report 155 Individual Laboratory Profile, American Proficiency Institute (API) testing records from 2022, the laboratory failed to achieve an overall testing even score of satisfactory performance (80% or greater) for two consecutive testing events in the subspecialty Endocrinology resulting in unsuccessful performance. The findings include: 1. A desk review of the CASPER Report 155 listed the following scores for the subspecialty Endocrinology in 2022: 2022 Event 2: Endocrinology - 75% 2022 Event 3: Endocrinology - 60% 2. A proficiency desk review of API proficiency testing records from 2022 had the following analyte scores resulting in unsuccessful overall performance (80% or greater) in the subspecialty Endocrinology: 2022 Event 2: Triiodothyronine: 0% 2022 Event 3: Thyroid Stimulating Hormone: 0% Triiodothyronine: 40%</p>
<p>D6000</p>	<p>MODERATE COMPLEXITY LABORATORY DIRECTOR CFR(s): 493.1403</p> <p>The laboratory must have a director who meets the qualification requirements of 493.</p>

1405 of this subpart and provides overall management and direction in accordance with 493.1407 of this subpart.

This CONDITION is not met as evidenced by:

Based on a desk review of the Certification and Survey Provider Enhanced Reporting (CASPER) Report 155 Individual Laboratory Profile and American Proficiency Institute (API) testing records, the laboratory director failed to ensure successful participation in an HHS-approved proficiency testing program for the Subspecialty Endocrinology, and the analytes Triiodothyronine and Thyroid Stimulating Hormone. Refer to D6016.

D6016

LABORATORY DIRECTOR RESPONSIBILITIES

CFR(s): 493.1407(e)(4)(i)

The laboratory director is responsible for the overall operation and administration of the laboratory, including the employment of personnel who are competent to perform test procedures, and record and report test results promptly, accurate, and proficiently and for assuring compliance with the applicable regulations. (e) The laboratory director must-- (e)(4)(i) Ensure that the proficiency testing samples are tested as required under Subpart H of this part;

This STANDARD is not met as evidenced by:

Based on a desk review of the Certification and Survey Provider Enhanced Reporting (CASPER) Report 155 Individual Laboratory Profile American Proficiency Institute (API) proficiency testing records, the laboratory director failed to ensure successful participation in a HHS approved proficiency testing program for the subspecialty Endocrinology for two consecutive events in 2022 (refer to D2108), and failed to achieve satisfactory performance for the analyte Triiodothyronine for two consecutive events in 2022 (refer to D2107).